Lu M, et al. -Researchers examined how ribavirin (RBV) and increased direct-acting antivirals (DAA) treatment duration influence the outcome of patients with chronic hepatitis C (HCV) in routine clinical care via analyzing data from the Chronic Hepatitis Cohort Study. They performed multivariable analysis of data from 4133 patients receiving any of the following: sofosbuvir (SOF); daclatasvir +SOF; grazoprevir +elbasvir; paritaprevir/ ritonavir +ombitasvir; simeprevir +SOF; and SOF +ledipasvir; SOF +velpatasvir ±voxilaprevir; and glecaprevir+pibrentasvir-all with/ without RBV. Outcomes revealed the reduced likelihood of SVR in independent correlation to diabetes, decompensated cirrhosis, and prior DAA treatment failure (TF). Increased likelihood of SVR was noted in correlation to longer treatment duration. Patients with GT3, previous DAA TF, or decompensated cirrhosis showed an increased likelihood of SVR in correlation to RBV.